ACOG
NASDAQAlpha Cognition Inc.
Price$9.69+0.10 (+1.10%)
04:30 PM07:45 PM
News · 26 weeks590%
2026-03-012026-08-23
Mix2290d
- Insider8(36%)
- Other7(32%)
- Analyst3(14%)
- SEC Filings2(9%)
- Earnings2(9%)
Latest news
25 items- INSIDERDirector Wills Robert James bought $96,200 worth of shares (10,000 units at $9.62), increasing direct ownership by 45% to 32,241 units (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- ANALYSTB. Riley Securities initiated coverage on Alpha Cognition with a new price targetB. Riley Securities initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $21.00
- SECSEC Form 10-Q filed by Alpha Cognition Inc.10-Q - Alpha Cognition Inc. (0001655923) (Filer)
- PRAlpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational UpdateZUNVEYL® net product revenue increased approximately 71% quarter-over-quarter to $6.0 million in the second quarter of 2026. Bottles dispensed increased approximately 37% quarter-over-quarter to 8,294, with monthly demand reaching 2,997 in June. Quarterly prescribers increased approximately 26% to 1,347 and repeat prescribers increased approximately 29% to 1,024, with approximately 76% prescribing in multiple months. Cash and cash equivalents totaled $41.4 million as of June 30, 2026, supporting the Company’s continued target of operating profitability in 2027 Company to host conference call and webcast today, August 13, at 4:30 p.m. ET. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha
- INSIDERLarge owner Opaleye Management Inc. bought $422,976 worth of shares (52,900 units at $8.00) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- PRAlpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business UpdateAlpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website. Following the release, management will host a conference call to review financial and operating results. Details for the conference call can be f
- PRAlpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s DiseaseAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" (ACI), or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer’s disease. The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition’s global intellectual property portfolio and may provide additio
- INSIDERLarge owner Opaleye Management Inc. bought $1,027 worth of shares (130 units at $7.90) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. bought $1,565,499 worth of shares (200,086 units at $7.82) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
- ANALYSTRaymond James initiated coverage on Alpha Cognition with a new price targetRaymond James initiated coverage of Alpha Cognition with a rating of Outperform and set a new price target of $20.00
- PRAlpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision SummitAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced Michael McFadden, Chief Executive Officer, will participate in the Late-Stage & Commercial CNS Small Cap panel discussion during the upcoming B. Riley Securities Mind, Muscle & Vision Summit, taking place July 16th in Boston, Massachusetts. The panel discussion will be held from 3:10 p.m. to 3:50 p.m. ET.For further information regarding this event or to schedule a 1x1 meeting during the summit, please reach out to your institutional representative at B. Riley. There will be no live webcast of
- INSIDERLarge owner Opaleye Management Inc. bought $976,490 worth of shares (152,533 units at $6.40) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
- SECAlpha Cognition Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Alpha Cognition Inc. (0001655923) (Filer)
- PRAlpha Cognition Announces Election of Dr. Robert Wills as Chairman of the BoardAlpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. "On behalf of the entire Board of Directors, we are pleased that Dr. Wills will serve as Chairman at this important time for Alpha Cognition," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "He brings a wealth of experience, strategic insight, and a deep understanding of our busi
- PRAlpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's DiseaseAlpha Cognition, Inc. (ACOG: NASDAQ) ("Alpha Cognition" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. RESOLVE is a multicenter, post-approval Phase 4 study designed to further evaluate the tolerability profile of ZUNVEYL in clinical practice, in patients with Alzheimer's disease. The study will collect safety and tolerability data and will also explore changes in Alzheimer's dise
- INSIDERLarge owner Opaleye Management Inc. bought $45,773 worth of shares (7,685 units at $5.96) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- INSIDERLarge owner Opaleye Management Inc. bought $58,596 worth of shares (10,054 units at $5.83) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- PRAlpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL® in Alzheimer's DiseaseIn a retrospective observational study based on provider assessments and chart review: Providers reported cognitive improvement in 92% of patients following initiation of ZUNVEYL Providers reported improvement in neuropsychiatric symptoms in 93% of patients after initiation of ZUNVEYL Providers reported delayed initiation or discontinuation of concomitant psychotropic medications in 80% of patients receiving ZUNVEYL Providers reported favorable changes in activities of daily living (ADLs) in 71% of patients following initiation of ZUNVEYL Providers reported improvements across sleep-related outcomes in 72% of patients following initiation of ZUNVEYL Providers reported favo
- INSIDERLarge owner Opaleye Management Inc. bought $434,714 worth of shares (73,738 units at $5.90) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- ANALYSTMaxim Group initiated coverage on Alpha Cognition with a new price targetMaxim Group initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $12.00
- INSIDERLarge owner Opaleye Management Inc. bought $140,545 worth of shares (24,376 units at $5.77) (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)
- INSIDERChief Operating Officer D'Angelo Lauren bought $20,160 worth of shares (3,500 units at $5.76), increasing direct ownership by 3% to 140,695 units (SEC Form 4)4 - Alpha Cognition Inc. (0001655923) (Issuer)
ACOG FAQ
3 questionsWhere does ACOG stock trade?
Alpha Cognition Inc. (ACOG) is listed on NASDAQ.What are analysts saying about ACOG?
Alpha Cognition Inc. has had 5 recent analyst actions on file. The most recent action was from B. Riley Securities: Buy with a $2100.00 price target on 2026-08-20. Recent price targets range from $1200.00 to $2100.00.How can I track ACOG on Quantisnow?
Quantisnow aggregates Alpha Cognition Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACOG to receive live email and push alerts on every new disclosure.